Rapid Fire Session 1
Zusammenfassungen erscheinen bald
- RF01-01 SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer
- RF01-02 A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: evaluation of dermal safety, intra-mammary drug distribution, and biologic effects
- RF01-03 PARSIFAL-LONG: Extended follow-up of hormone receptor-positive /HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study
- RF01-04 Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification
- RF01-05 Functional assessment of RAD51 foci and replication fork dynamics in PARPi resistant BRCA1/2 mutated breast cancer
- GS01-06 Advancing ERF01-06 Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer: a multicenter phase II trial based on a Bayesian adaptive randomized designvidence of the Associations Between Specific Benign Breast Diagnoses and Future Breast Cancer RIsk
- RF01-07 The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2- breast cancer or TNBC
- RF01-08 A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE)
John Robertson, Teimuraz Gogitidze, Zaza Katashvili, et al.
RF01-01 SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer
Zusammenfassung folgt
Oukseub Lee, Latifa Bazzi, Yanfei Xu, et al.
RF01-02 A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: evaluation of dermal safety, intra-mammary drug distribution, and biologic effects
Zusammenfassung folgt
Antonio Llombart-Cussac, José Manuel Pérez-García, Meritxell Bellet-Ezquerra, et al.
RF01-03 PARSIFAL-LONG: Extended follow-up of hormone receptor-positive /HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study
Zusammenfassung folgt
Senthil Damodaran, Fabrice André, Nisha Unni, et al.
RF01-04 Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification
Zusammenfassung folgt
Elizabeth Harvey-Jones, Maya Raghunandan, Luisa Robbez- Masson, et al.
RF01-05 Functional assessment of RAD51 foci and replication fork dynamics in PARPi resistant BRCA1/2 mutated breast cancer
Zusammenfassung folgt
Hongnan Mo, Xiaoying Sun, Jingtong Zhai et al.
GS01-06 Advancing ERF01-06 Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer: a multicenter phase II trial based on a Bayesian adaptive randomized designvidence of the Associations Between Specific Benign Breast Diagnoses and Future Breast Cancer RIsk
Zusammenfassung folgt
Piha-Paul Sarina, Binghe Xu, Ying Fan, et al.
RF01-07 The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2- breast cancer or TNBC
Zusammenfassung folgt
Jyoti Bajpai, Venkatesh Kapu, Sushmita Rath, et al.
RF01-08 A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE)
Zusammenfassung folgt